Document is current
Any future updates will be listed below
-
Authors
Cai, Lin
Wang, Xiaohua
Zhang, Litao
Zhang, Guoqiang
Wu, Liming
Yang, Baoqi
Meng, Zudong
Shi, Jihai
Han, Guangming
Wei, Aihua
Li, Shanshan
Zhao, Yi
Su, Juan
Wei, Nianjin
Liu, Siying
Liu, Ran
Liu, Wei
Fang, Min
Zhang, Xiaoqing
Zhang, Jianzhong https://orcid.org/0000-0002-5485-682X
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2300075645 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study
https://doi.org/10.1007/s13555-026-01694-1
-
Funding
Funding for this research was provided by:
Shanghai Hansoh BioMedical Co., Ltd
- License Information
-
More Information
Article History
Received: 14 January 2026
Accepted: 11 February 2026
First Online: 22 March 2026
Declarations
:
: Jianzhong Zhang has served as an advisor, speaker, or consultant and receives honorarium for Pfizer Investment Co. Ltd., Novartis Pharmaceuticals (China), Sanofi China, LEO Pharma (Shanghai) Co. Ltd., GSK(China) Investment Co. Ltd., Eli Lilly and Company (China), Bristol-Myers Squibb (China) Investment Co. Ltd., Keymed Biosciences (Chengdu) Ltd., Akeso Biopharma Co. Ltd., and Kintor Pharmaceutical Ltd. Siying Liu, Ran Liu, Wei Liu, and Xiaoqing Zhang are employees of Shanghai Hansoh BioMedical Co., Ltd. Nianjin Wei and Min Fang (current affiliation: Atom Therapeutics Co., Ltd.) are employees and former employees of Qyuns Therapeutics Co., Ltd, respectively. All other authors, Lin Cai, Xiaohua Wang, Litao Zhang, Guoqiang Zhang, Liming Wu, Baoqi Yang, Zudong Meng, Jihai Shi, Guangming Han, Aihua Wei, Shanshan Li, Yi Zhao, and Juan Su, declared no related conflicts of interest.
: The study protocol was approved by the independent ethics committee at each study site (approval number in leading site: 2023PHA106-002). The study was conducted in accordance with the approved protocol, Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable local regulations. All participants provided the written informed consent before enrollment.
